Generated by AI
AVITA Medical, Inc. is a therapeutic acute wound care company focused on regenerative solutions for skin restoration and wound healing. Its flagship RECELL System uses a patient’s own skin cells to create a spray-on cell suspension at the point of care for the treatment of thermal burn wounds, full-thickness skin defects, and stable depigmented vitiligo lesions. The company also markets PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix, supporting surgeons and clinicians in burn care, trauma care, and reconstructive procedures. AVITA Medical serves hospitals, treatment centers, and distributors across the United States, Japan, the European Union, Australia, and the United Kingdom. Headquartered in Valencia, California, AVITA Medical specializes in technologies designed to improve wound coverage and support clinical recovery in acute care settings.
Website28159 Avenue Stanford
Valencia, CA, 91355
United States
The latest articles about RCEL.
If you had backed AVITA Medical at the very start of 2026, the result would look dramatic on any brokerage screen. Holding AVITA Medical from the start of the year would have returned 393.4%, including dividends. That kind of move invites a hard look at what early shareholders were really judging. If the Medicare reimbursement dispute, trauma expansion push and cost cuts were all still unresolved on 2026-01-01, which of those uncertainties would you have leaned into and which would you have...
Summary of Aug 25's posts. Generated by AI.
No summary yet.
Summary of Aug 7's posts. Generated by AI.
Summary of Aug 25's posts. Generated by AI.
Investors talking about RCEL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.